Trial Profile
Long term safety and efficacy of galantamine in Alzheimer's disease (extension INT-8)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 22 Oct 2007 Status changed from in progress to completed.
- 15 Oct 2006 New trial record.